Cellevate, a biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, will pre-launch the world’s first nanofiber microcarrier for gene therapy at CPHI Milan, October 8-10, 2024.
 
By providing up to 60 times more surface area for cell growth than conventional systems, Cellevat3d nanofiber microcarriers are designed to increase yield and productivity in upstream bioprocessing of gene therapy applications. Engineered for stirred tank bioreactors, Cellevat3d nanofiber microcarriers support a wide range of upstream bioprocessing applications including gene therapy, pluripotent stem cell (PSC) expansion, organoid formation, HEK-based recombinant proteins and HEK-based vaccine production.
 
“Scalable, sustainable and single use, Cellevat3d nanofiber microcarriers closely mimic the human extracellular environment, providing higher cell densities and enhancing yield for viral vector production compared to current standard microcarriers based processes,” says Laura Chirica, PhD CEO, of Cellevate. “Our nanofiber microcarriers effectively address the key challenges of low productivity and high manufacturing costs facing the industry. With this pre-launch of Cellevat3d nanofiber microcarriers starter pack, at CPHI Milan, we’re excited to provide early access to a completely new category of cell culture systems currently unavailable on the market. Cellevat3d nanofiber-based cell culture systems truly have the potential to transform biomanufacturing for advanced therapies and take a significant step toward making these therapies more accessible to patients.”
 
Cellevat3d nanofiber microcarriers will be available for pre-order at CPHI Milan from October 8-10, 2024. The official commercial product launch will follow at BIO-Europe in Stockholm, Sweden, from November 4-6, 2024.